Key Highlights
● Revenue rose and adjusted Earnings strengthened, helped by OneOncology
● Dividend was raised
● New reporting structure groups specialty Assets together
● New-year guidance reflects pending divestitures and list-price cuts
Cencora, Inc. (NYSE:COR), a heavyweight in the pharmaceutical distribution corner of healthcare, closed its fiscal year with a report that was as much about corporate architecture as about earnings. The Conshohocken, Pennsylvania, company posted higher fourth-quarter Revenue and a strong rise in adjusted diluted earnings per share, declared a larger quarterly dividend, and issued guidance for the new fiscal year. It also confirmed that, starting with the coming quarter, it will report under a segment structure designed to give its specialty businesses a far clearer profile.
President and Chief Executive Robert Mauch described the fiscal year as "a pivotal year for Cencora" in the earnings release. On the conference call, he explained that the company has combined specialty assets that previously sat in different parts of the organization under different leaders. He said the goals are faster execution, closer customer relationships and better visibility for shareholders. The change gives investors a new way to judge the company, separating the steady logistics foundation from the quicker-growing and higher-margin specialty activities.
A Clean Beat Against Pre-Report Forecasts
Market data dated late October set out consensus forecasts for adjusted earnings per share and revenue. The reported adjusted figure and revenue both finished above those marks, and adjusted earnings also landed above the higher whisper figure published in the same preview. Adjusted Diluted Earnings per Share rose at a strong double-digit rate from the prior-year quarter, according to the company's release, while revenue grew at a mid-single-digit pace.
The preview had framed the report around several issues: whether core US Operating Income growth would continue, whether OneOncology and Retina Consultants of America would continue to run ahead of plan, and how list-price cuts and lower sales to a large mail-order customer would weigh on revenue. Going into the release, the shares had gained since the prior report while the S&P 500 had fallen, and they traded a little below their high.
Gross Profit Tells the Quarter's Story
Margin gains were the standout feature. Adjusted Gross Profit rose at a rate well above revenue, lifting adjusted gross Margin by a meaningful amount. The company attributed that mainly to US Healthcare Solutions, assisted by the OneOncology acquisition, with lower-margin sales of glucagon-like peptide drugs acting as a partial offset. Adjusted operating expenses rose at a similar pace, again largely because of OneOncology, so that adjusted operating income still rose at a strong double-digit rate.
Reported results looked dramatically different, largely because of comparisons. GAAP operating income jumped from a very small level a year earlier, when the quarter carried a large Goodwill Impairment on the PharmaLex business. GAAP diluted earnings per share moved from a loss to a profit. The latest quarter recorded no impairment, but tax items had a visible effect: a benefit tied to the pending MWI divestiture was more than offset by an unfavorable valuation adjustment on Swiss deferred tax assets, leaving the GAAP tax rate well above the adjusted rate.
Below the operating line, net interest expense rose substantially because of senior notes and variable-rate term loans used to fund part of OneOncology, together with lower interest income. Share repurchases helped reduce the diluted share count. Those factors together explain how adjusted earnings per share grew almost in step with adjusted operating income.
How the Existing Segments Performed
US Healthcare Solutions delivered the bulk of revenue and operating income. Revenue growth reflected market growth, mainly unit volume, including specialty products sold to health systems and physician practices along with glucagon-like peptide products. Lower Brand manufacturer prices and reduced sales to the large mail-order customer provided offsets. Chief Financial Officer Boratto, identified by surname in the transcript, said core US growth was stronger once acquisitions and a lost oncology customer were excluded.
International Healthcare Solutions recorded growth across all its businesses. Its operating income rose mainly on Canadian operations and global specialty logistics, and constant-currency growth was somewhat better than reported growth. The Other category, which contains Profarma and MWI Animal Health, also advanced, although its profit gain was helped by lower Depreciation once MWI was classified as held for sale, and revenue reflected the divestiture of US Consulting Services in April.
For the full fiscal year, revenue rose at a mid-single-digit rate and adjusted diluted earnings per share climbed at a double-digit rate. The GAAP and adjusted full-year earnings figures landed close together because of offsetting items: the GAAP result included a large remeasurement gain on the company's previously held Equity stake in OneOncology, alongside other items such as an impairment mostly related to US Consulting Services. Cash generation was solid, with adjusted free Cash Flow finishing ahead of guidance, according to the call, and the company returned cash through repurchases and dividends.
The New Map: Distribution on One Side, Specialty on the Other
From the first quarter of the new fiscal year, Pharmaceutical Distribution and Services will encompass US and international wholesale distribution and related services for health systems, retail pharmacies and alternate sites of care. Specialty Pharmaceutical and Provider Services will contain specialty distribution to physician practices and management services organizations, World Courier and third-party logistics services, Innomar and strategic elements of PharmaLex. MWI, Profarma and the remaining PharmaLex components under strategic review will sit in Other, which is not a reportable segment.
The company provided long-term ambitions to match. It reaffirmed its enterprise goals for adjusted operating income and adjusted earnings per share growth, and introduced segment goals of mid-single-digit operating income growth for distribution and mid-teens growth for specialty. The finance chief said management services organizations represented a relatively small but meaningful slice of operating income in the fiscal year just ended, in a remark bearing on why specialty margins sit above those of distribution. Those margins also reflect the inclusion of World Courier, third-party logistics and consulting activities.
Where Full-Year Costs and Credits Landed
The full-year income statement contains several items that are easy to overlook. Adjusted operating expenses rose strongly, driven by OneOncology and by the Retina Consultants of America Acquisition completed in January of last year. Net interest expense climbed substantially. GAAP gross profit benefited from a larger LIFO credit, partly offset by lower antitrust settlement gains.
The fiscal year also included a reduction in opioid Liability and a Credit from a derivative lawsuit settlement. Items of this sort tend to be excluded from adjusted measures, which is why the company presents reconciliations in its release. Cencora explained that it does not provide GAAP guidance because certain items, such as LIFO and future acquisition amortization, cannot be reasonably estimated. Together, these disclosures show why the adjusted figures remain the market's main reference point, even though the GAAP results carry the statutory weight.
The international Business deserves its own note. For the full year, International Healthcare Solutions recorded revenue and operating income growth at high single-digit rates. Market data had said a stronger dollar trimmed growth expectations there, and asked whether World Courier and European third-party logistics could sustain double-digit operating income growth. Under the new structure, those logistics activities move to the specialty segment, while European wholesale joins distribution, which means historical comparisons will require some translation in coming quarters.
Doubling Down on Oncology and Retina
Mauch made the strategic case in market terms. He said specialty Biologics now make up more than half of US pharmaceutical spending, and that a large number of new oncology products are expected before the end of the decade. OneOncology, acquired in February, joined Retina Consultants of America in the provider platform. The company also has an agreement covering American Oncology Network, which the release says has a large roster of oncology providers spread across many states, and it announced iSouth Retina in March. Both pending transactions are excluded from new-year guidance and will be added when they close.
The boundaries of this strategy were also clear. Mauch said the company does not see other therapeutic areas as equally pharmaceutical-centric for this kind of model, so it does not currently see a similar case for practice management outside oncology and retina. Asked about infusion assets, he said Cencora will keep supporting infusion customers but does not need to own that capability. He also identified Biosimilars as the more attractive opportunity than small-molecule generics, calling the Part B biosimilar "the sweet spot" for the company.
An analyst asked about reimbursement following the US election, and Mauch said the company will engage with the new Congress. A summary of the call said management is monitoring possible policy changes affecting specialty providers, and that no fiscal impact was quantified. Market data had separately flagged drug discount rules and Part B pricing as policy risks.
Reading the New-Year Guidance
Adjusted diluted earnings per share guidance for the new fiscal year implies growth at a high single-digit rate, and revenue growth is expected at a low to mid-single-digit rate, while adjusted operating income is projected to grow more slowly than the company's long-term ambition. Specialty is expected to grow operating income strongly, helped by the remaining months of OneOncology's inclusion, while distribution operating income growth is expected to be modest and below its new long-term goal. The finance chief attributed that gap to a customer Volume shift and foreign exchange effects.
A significant portion of the slowdown reflects portfolio choices. The outlook assumes a closing of the MWI Merger with Covetrus at the end of March and the disposal of the Profarma stake in the first fiscal quarter. Together those changes reduce consolidated revenue growth, and the businesses in Other subtract meaningfully from operating income growth. Excluding the MWI effect, the company said earnings per share growth would land in a higher range that overlaps its long-term goal.
Manufacturer list-price cuts are another continuing factor. They represented a sizeable headwind to fourth-quarter revenue, and management expects a broadly similar effect in the new fiscal year. Because list-price changes influence revenue more directly than profit, investors may find operating income a more useful gauge of underlying performance. Net interest expense guidance sits at or above the latest fiscal year's level, reflecting the financing of OneOncology.
What Analysts Pressed Management to Explain
The question session revealed where investors see uncertainty. Elizabeth Anderson of Evercore asked why the company chose to resegment now, and Mauch pointed to market growth in biologics and oncology launches. Glen Santangelo of Barclays asked how much of specialty's mid-teens ambition reflects volume as opposed to acquisitions, and the finance chief described a combination of market growth, organic growth in practice management and smaller tuck-in transactions. Allen Lutz of BofA asked about synergies between Retina Consultants of America, OneOncology and World Courier, and Mauch replied that the thesis is growth rather than cost savings.
Charles Rhyee of TD Cowen raised the generic drug cycle. Mauch said that small-molecule launches in Part D chiefly affect revenue, and that guidance already includes launch assumptions. Kevin Caliendo of UBS (NYSE:UBS) asked about the OneOncology run rate, a wholesale initiative at Cigna (NYSE:CI) and Option Care. The response was that Option Care is an existing customer whose impact would fall within distribution guidance, and Mauch said all customer relationships are reflected in guidance, declining to comment further. Market data added that a possible change involving Option Care would shift results within the existing range. Taken together, the responses suggest management believes the outlook already absorbs those moving parts, though only subsequent quarters can test that view.
Management also provided a near-term marker by guiding to adjusted diluted earnings per share for the first fiscal quarter. It will next appear before investors at the J.P. Morgan Healthcare Conference in January, according to the release, and the coming fiscal quarter will be the first reported under the new structure.
Capital Plans and an Unexplained Figure
The board raised the quarterly Dividend at a double-digit rate, with payment set for the end of November. Management said the Capital deployment framework remains unchanged, covering internal investment, strategic acquisitions, opportunistic repurchases and a growing dividend. Adjusted free cash flow is expected to fall modestly in the new fiscal year, while capital expenditures remain elevated in dollar terms, funding the US Supply chain, information technology and infrastructure for practice management.
Analysts pressed on a capital deployment item in the release's long-term table that lacked explanation. An analyst connected it with capital spending, and the finance chief replied, "It was not intended to be CapEx growing," adding that it referred to capital deployment. The transcript leaves the measure otherwise undefined. Another analyst asked whether the coming year's capital spending would be a temporary spike; the answer was that it would not. Those exchanges indicate that the Investment phase, like the new reporting structure, will remain under close observation as the company's next set of quarterly results approaches.






Please wait processing your request...